European practitioners will gain new methods for treatment after the June meeting of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) where the panel recommended several novel drug candidates and new indications for existing drugs.
Celgene's gene therapy Abecma (idecabtagene vicleucel) was for example nominated for conditional marketing authorization as a fourth-line therapy for bone marrow cancer. CHMP also had a positive view of Biomarin's Voxzogo (vosoritid) for the day-to-day treatment of children with achondroplasia. This drug might eventually challenge Transcon CNP, which is produced by Danish biotech firm Ascendis, if the latter reaches the market.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Analytical Senior Scientist 
2 Sales Representatives and Product Specialists 
Communications Consultant 
Quality System Manager 
Clinical Project Manager 
Senior Chemical Safety Advisor 
Key Account Manager, Europe and Asia 
Senior IT Network Engineer 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Senior Manager, Clinical Trial Budget 
Production Director 
Industrial Designer- Design Engineer 
(Senior) Drug Substance Specialist